The Chiesi Total Care Program Assists With:
Payer coverage and access
Verify patient's benefit coverage and financial assistance eligibility (including Commercial insurance, Government Insurance, and No insurance)
Prior authorization and support
Call 1-833-670-6464 to:
- Determine documentation needed by the patient's health plan
- Navigate payer appeals and exceptions
Financial assistance
Options are tailored to the individualized needs of your patients
A dedicated Total Care team that includes:
- Patient service coordinators who assist those prescribed FILSUVEZ
- Nursing support
- Worry-free refills including 24-hour pharmacist availability and medication delivered right to your patient's door
Resource center
Our resources include helpful links that provide more detailed information on Epidermolysis Bullosa and FILSUVEZ
Access and Support Services
Download a FILSUVEZ Starter Kit today
Helpful Links for Your Patients
FILSUVEZ® (birch triterpenes) topical gel
Indication and Important Safety Information
INDICATION
FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.
IMPORTANT SAFETY INFORMATION
Warnings & Precautions
Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.
Adverse Reactions
The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).
Patient Counseling Information
Please refer to Prescribing Information for administration instructions.
To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
Indication and Important Safety Information
INDICATION
FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older.
IMPORTANT SAFETY INFORMATION
Warnings & Precautions
Local hypersensitivity and skin reactions have been reported in patients treated with FILSUVEZ, including urticaria and dermatitis. If signs or symptoms of hypersensitivity occur, discontinue use immediately and initiate appropriate therapy.
Adverse Reactions
The most commonly reported adverse reaction in clinical trials was pruritus and pain at the wound application site (7.3%).
Patient Counseling Information
Please refer to Prescribing Information for administration instructions.
To report SUSPECTED ADVERSE REACTIONS, contact Chiesi USA Inc. at 1-888-9260 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.